Friday, April 26, 2024
4/26/2024
PROJECT SUMMARY/ABSTRACT The goal of this F31 application is to investigate intracellular signaling events that promote death of tumor-specific T cells in vivo. To achieve appropriate immune homeostasis, populations of effector T cells and regulatory T cells must be tightly controlled. Cancer is one disease state where regulatory T cells can suppress effector T cells and prevent elimination of tumors. To overcome immune suppression and tolerance that occurs during cancer, adoptive T cell therapies have been introduced clinically, including adoptive transfer of CAR (chimeric antigen receptor) T cells. CAR T cells contain TCRs with tumor antigen specificity, a signaling component of the TCR (CD3 zeta chain) as well as one or more co-stimulatory domains (such as CD28). CAR T cells are efficiently activated and have been very effective for the treatment of some cancers, especially hematologic cancers. One problem, however, is that CAR T cells often do not persist in vivo, especially for solid tumors, and have been shown to undergo activation induced cell death (AICD). Currently, knowledge of the mechanisms of CAR T cell death and strategies to promote CAR T cell survival are limited. We discovered a novel form of AICD that occurs when effector T cells are stimulated on anti-CD3 and anti-CD28 coated plates. This process is dependent on p53 and is termed PICA (p53-induced CD28 dependent T cell apoptosis). We found that that effector T cells die during PICA, but that Foxp3+ regulatory T cells are resistant to PICA through TGF-ß signaling. Our data also show that effector CAR T cells stimulated with large numbers of antigen-expressing cells (>1:20) undergo cell death. The CAR T cells that survive this high dose antigen stimulation are Foxp3+. We therefore hypothesize that CAR T cells undergo PICA when stimulated with high dose antigen. Elucidating this mechanism of CAR T cell death can help us better design CAR T cells that persist and kill more efficiently in vivo. While investigating PICA in effector T cells, we discovered that the protein RasGRP1, a Ras activator, is highly elevated in effector T cells after repeated stimulation. Tregs maintain low levels of RasGRP1, and this is dependent on TGF-ß signaling. We currently do not know the function and phenotype of CAR T cells that survive high dose antigen stimulation from solid tumors in vivo, and if RasGRP1 promotes CAR T cell death in vitro and in vivo. Aim 1 will determine if CAR T cells that survive stimulation by solid tumors in vivo are Foxp3+ and functionally suppressive, due to TGF-ß signaling. Aim 2 will determine if RasGRP1 promotes death in CAR T cells, and if engineering a CAR with dominant negative RasGRP1 can rescue CAR T cell death and promote tumor killing in vivo. Overall, we expect this study to illuminate mechanisms of CAR T cell death, which can aid in promoting CAR T cell survival in solid tumors. Additionally, this study will test the use of a novel CAR construct, which we predict will enhance CAR T cell survival and could inform future design of CAR T cells that are used clinically.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
